Targets › CD59
1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Aug 2029.
Potent inhibitor of the complement membrane attack complex (MAC) action, which protects human cells from damage during complement activation. Acts by binding to the beta-haipins of C8 (C8A and C8B) components of the assembling MAC, forming an intermolecular beta-sheet that prevents incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore..; FUNCTION: The soluble form from…. (UniProt, P13987)
Open in Phaseline: the race on CD59, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johnson & Johnson (Janssen) | JNJ-81201887 AAV5-delivered CD59 complement regulator | CD59 | Phase 2 | Geographic Atrophy | Aug 2029 |
Geographic Atrophy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.